Cancer Treatment Centers of America, popularly known as CTCA, is a hospital network in the United States that focuses on cancer care. It has more than 30 years of expertise in designing personalized treatment and care for its patients. Interestingly, the network offers a wide range of jobs to healthcare and non-healthcare professionals. It communicated its need for service-oriented professionals who are ready to go an extra mile to ensure the personalized care a unique experience. The network needs a large number of registered nurses to its network with an excellent pay structure. Currently, the hospital group hires Infusion registered nurses to its Scottsdale clinic.
The full-time opportunity demands a minimum of two years expertise in an oncology environment. People who wanted to join the network should hold the Arizona Registered Nurse certification. Patient care technician is another major vacancy reported in the network. The part-time opportunity requires high school graduation and current BLS to join the network. Additionally, an experience of at least six months as a Nurse Aide especially from a clinic or hospital environment. People who completed the training program for Nurse Aid can also apply for the vacancy. Currently, the hospital network is hiring for its Newnan and Tulsa locations, and the job is offering an excellent salary above the national average.
Clinical Scheduling coordinator is another major vacancy the network wants more people into its network. The full-time vacancies are similar to clerical roles and offer fixed schedule and hours of work. People who have completed high school diploma are eligible to apply for the job. Additionally, CTCA prefers people with three years of experience in medical scheduling and holders of Business Associates degree. Infection Control Practitioner is another major vacancy reported by the cancer treatment network. The full-time opportunity is for Philadelphia location and Certification in Infection Control, or CIC is a must to apply for the job. The job also needs a clinical background experience including medical technologist, registered nurse, and more.
While coming to the education, the applicants should be bachelors in microbiology, epidemiology, or any other subject related to healthcare or life science with a minimum experience of five years in infection control area. Another major opportunity reported with the network is a switchboard operator. The full-time opportunity is for Goodyear, AZ, and the applicants should have completed GED or high school diploma. People from the customer service background are preferred for the job. Business Services Manager is another major opportunity that is full-time as well as having fixed day hours. The job also needs GED or high school diploma and at least four years of exposure in a healthcare office or related offices. The applicants should have experience in registration, collection, and insurance. The opportunity is for Goodyear, AZ, location.
Mikhail Blagosklonny and Andrei V. Gudkov created an online medical journal that is now being used by the majority of scientists around the world because of its reliability and convenience. They also serve as the online medical journal’s editors in chief, responsible for reviewing every article that is being submitted by contributors around the world. They named their online medical journal as Oncotarget, because it initially requested information about cancer from the contributors, who are mostly oncologists, but since 2017, there are other scholarly articles found on the online medical journal that tackles about other deadly diseases, and it is no longer focused on articles about cancer alone. Oncotarget is also known as the first peer-reviewed online medical journal, which means that a panel of scientists is reviewing each article that is being sent to Oncotarget. It allows the online medical journal to have a collection of high-quality articles that tackles about fatal human diseases. Learn more about Oncotarget at Research Gate.
In 2010, Mikhail Blagosklonny and Andrei V. Gudkov had a conversation about creating a system that would enable oncologists from around the world to meet up in a virtual platform where they can share their ideas. They started to think about creating a website, which would, later on, be referred to as Oncotarget, and they managed to get a lot of readers from around the world after the online medical journal was launched. The names Mikhail Blagosklonny and Andrei V. Gudkov became well-known among the scientific community because of their creation. After making it live, scientists from around the world now have the chance to send what they know about cancer and other fatal diseases to the system’s database, and it will be reviewed by the scientific community. If the articles made it through the selection process, other scientists from around the world would be able to access the document using only a computer and a personal computer.
The invention of Mikhail Blagosklonny and Andrei V. Gudkov made sharing and brainstorming ideas among the scientists an easy task, and it is seen as the future of communication and medicine, where the two industries will integrate for the benefit of humankind. Follow Oncotarget journal on Twitter.
In a recent interview with Inspirey.com, founder and CEO of Seattle Genetics sat down to share his some of his secrets to success. Always passionate about helping others, Clay Siegall says he has always had a passion for medicine. The desire to fight illness and help others overcome disease is what led the entrepreneur to create Seattle Genetics.
After watching a loved one battle cancer first hand, Siegall was determined to make a difference and revolutionize the cancer treatment industry. Treatment is meant to help improve the quality of life, but Siegall recalls a worsening of his loved one’s condition following the start of treatment. As in most cases, the chemotherapy had also made the symptoms of the patient’s condition worse.
Fueled by the desire to make a change, he began researching other treatment options. To his surprise, the options seemed to be few and were not accessible to all patients. Seattle Genetics was not only created to improve the quality of cancer treatment but to also bridge the gap between proper education and diverse treatment options. Seattle Genetics uses a combination of monoclonal antibody-based therapies and anti-drug conjugates, or ACDs to help patients fight cancer. Unlike chemotherapy, ACDs target only the cells that cause cancer thus reducing the effects of toxins released during traditional chemotherapy.
After graduating from the University of Maryland with a bachelors degree in zoology, Sigeall went on to earn a Ph.D. in genetics from The George Washington University. His combination of compassion and education would serve as fuel in his fight to improve cancer treatment. The company’s newest development, brentuximab vedotin or ADCETRIS is making a breakthrough in the cancer treatment industry. Under the guidance of Dr. Clay Siegall, Seattle Genetics has established themselves as leaders in cancer treatment, and in healthcare. Currently, there are more than 20 new ACDs using Seattle Genetics technology in the clinical development stages. Since their 1998 launch, the company has raised more than $675 million towards research and the development of new treatment therapies.